Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early as part of a global realignment of Sponsor's clinical development programs. This decision is not related to any safety concerns regarding the IP.

Conditions

Primary Progressive Multiple Sclerosis

Interventions

DRUG: GA Depot 40mg once monthly
DRUG: GA Depot 25mg once monthly

Sponsor

Mapi Pharma Ltd.